Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518144 | 0.89 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL3520920 | 0.84 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL3175625 | 0.80 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3525111 | 0.79 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL3522067 | 0.79 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL13255232 | 0.79 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL3175984 | 0.78 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL3661531 | 0.78 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL3520365 | 0.77 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3520870 | 0.75 | CNR1 (0.71) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763732-B2 | 7-Chloro-3-({5-[N-(morpholin-1-ylcarboxamido)methyl]aminomethyl}-([1,2,4]-thiadiazol-3-yl))-1-(tetrahydropyran-4-yl)methyl-1H-indole, hydrochloride salt; treatment of pain | N.V. ORGANON (NL) | 2010-07-27 | — | — | US | disclosed |
| US-20090029984-A1 | SYNERGISTIC COMBINATION FOR THE TREATMENT OF PAIN (CANNABINOID RECEPTOR AGONIST AND OPIOID RECEPTOR AGONIST) | N.V. ORGANON (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20070082931-A1 | Indole derivatives | AKZO NOBLE N.V. (NL) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082931-A1 | Indole derivatives | IDO1, TPH1, IDO2 | CNR1 36/4885CNR2 24/4885 |
| US-20090029984-A1 | SYNERGISTIC COMBINATION FOR THE TREATMENT OF PAIN (CANNABINOID RECEPTOR AGONIST AND OPIOID RECEPTOR AGONIST) | CNR1, OPRL1, CNR2 | CNR1 1/4885CNR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.